GlucoTrack (GCTK)
NASDAQ:GCTK
Top Page
GlucoTrack
(NASDAQ:GCTK)
Select Model
Select Model
Rating:43Neutral
Price Target:
$0.63
▼(-67.51% Downside)
Action:ReiteratedDate:04/01/26
Score is weighed down primarily by weak financial performance (near-zero revenue, sizable losses, and ongoing cash burn) and a strongly bearish technical setup (well below major moving averages with negative momentum). Positive corporate milestones (FDA submission preparation and strengthened IP) provide some offset, but valuation signals are not supportive due to limited meaningful P/E and no dividend data.
Positive Factors
Strengthened IP portfolio
Issued patents on core sensor chemistry, intravascular lead design and low-power electronics create a multi-year intellectual property moat for the implantable CBGM platform. This protects differentiation versus subcutaneous rivals and supports exclusive commercialization pathways and licensing options.
Negative Factors
Near-zero revenue & widening losses
The company has not reached meaningful commercialization and reports essentially no revenue while losses have widened materially. Persistent negative gross profit and rising net losses undermine self-sufficiency, increasing reliance on external capital and extending commercialization timelines.
Read all positive and negative factors
Positive Factors
Negative Factors
Strengthened IP portfolio
Issued patents on core sensor chemistry, intravascular lead design and low-power electronics create a multi-year intellectual property moat for the implantable CBGM platform. This protects differentiation versus subcutaneous rivals and supports exclusive commercialization pathways and licensing options.
Read all positive factors
GlucoTrack (GCTK) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$1.67M
Dividend YieldN/A
Average Volume (3M)2.54M
Price to Earnings (P/E)―
Beta (1Y)1.85
Revenue GrowthN/A
EPS Growth60.83%
CountryUS
Employees11
SectorHealthcare
Sector Strength45
IndustryMedical - Instruments & Supplies
Share Statistics
EPS (TTM)-3.98
Shares Outstanding1,944,279
10 Day Avg. Volume100,775
30 Day Avg. Volume2,541,249
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)1.23
Price to Sales (P/S)0.00
P/FCF Ratio-0.23
Enterprise Value/Market Cap-4.10
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit245.07
Enterprise Value/Ebitda0.43
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
GlucoTrack Business Overview & Revenue Model
Company Description
GlucoTrack, Inc., a medical device company, designs, develops, and commercializes non-invasive glucose monitoring devices for use by people suffering from diabetes and pre-diabetics in Israel and internationally. It develops GlucoTrack glucose mon...
How the Company Makes Money
null...
GlucoTrack Financial Statement Overview
Summary
Income Statement
8
Very Negative
Balance Sheet
36
Negative
Cash Flow
15
Very Negative
| Breakdown | Dec 2025 | Mar 2025 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | -36.00K | -13.00K | -23.00K | 0.00 |
| EBITDA | -16.05M | -21.98M | -7.08M | -4.41M | -3.94M |
| Net Income | -19.39M | -22.60M | -7.10M | -4.43M | -4.07M |
Balance Sheet | |||||
| Total Assets | 7.84M | 5.93M | 4.91M | 2.44M | 6.26M |
| Cash, Cash Equivalents and Short-Term Investments | 7.38M | 5.62M | 4.49M | 2.31M | 6.06M |
| Total Debt | 33.00K | 267.00K | 196.00K | 195.00K | 250.00K |
| Total Liabilities | 5.01M | 18.93M | 1.71M | 1.21M | 1.11M |
| Stockholders Equity | 2.83M | -13.00M | 3.20M | 1.23M | 5.16M |
Cash Flow | |||||
| Free Cash Flow | -15.34M | -12.59M | -6.56M | -3.73M | -3.77M |
| Operating Cash Flow | -15.24M | -12.49M | -6.56M | -3.73M | -3.77M |
| Investing Cash Flow | -96.00K | -104.00K | 0.00 | 1.00K | -1.00K |
| Financing Cash Flow | 17.04M | 13.74M | 8.73M | 0.00 | 0.00 |
GlucoTrack Technical Analysis
Negative
1.93
Price Trends
1.62
Negative
3.25
Negative
4.77
Negative
Market Momentum
-0.26
Negative
30.92
Neutral
14.37
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GCTK, the sentiment is Negative. The current price of 1.9300000000000002 is above the 20-day moving average (MA) of 1.10, above the 50-day MA of 1.62, and below the 200-day MA of 4.77, indicating a bearish trend. The MACD of -0.26 indicates Negative momentum. The RSI at 30.92 is Neutral, neither overbought nor oversold. The STOCH value of 14.37 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for GCTK.
GlucoTrack Risk Analysis
GlucoTrack disclosed 35 risk factors in its most recent earnings report. GlucoTrack reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
GlucoTrack Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
54 Neutral | $33.50M | -1.12 | -85.01% | ― | -16.59% | 43.20% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
47 Neutral | $1.40M | -2.02 | ― | ― | ― | ― | |
43 Neutral | $1.67M | -0.18 | ― | ― | ― | 60.83% | |
42 Neutral | $26.52M | -1.22 | -534.91% | ― | 63.53% | 12.49% |
* Healthcare Sector Average
GCTK
GlucoTrack
0.86
-8.07
-90.37%
EKSO
EKSO BIONICS
9.40
3.60
62.07%
FEMY
Femasys
0.44
-0.71
-61.83%
WOK
WORK Medical Technology Group LTD
1.15
-4,323.85
-99.97%
GlucoTrack Corporate Events
Business Operations and StrategyProduct-Related AnnouncementsRegulatory Filings and Compliance
GlucoTrack Prepares FDA Submission for Implantable CBGM Trial
Positive
Mar 27, 2026
On March 27, 2026, Glucotrack recapped a series of 2024–2025 milestones that have positioned it to submit an Investigational Device Exemption to the U.S. Food and Drug Administration in the second quarter of 2026 for a U.S. clinical trial of...
Business Operations and StrategyPrivate Placements and FinancingRegulatory Filings and ComplianceShareholder Meetings
GlucoTrack Shareholders Approve Capital Flexibility and Auditor Ratification
Positive
Mar 13, 2026
On March 12, 2026, Glucotrack shareholders approved multiple capital and governance measures at a special meeting that reached quorum with about 44.1% of eligible common shares represented. Investors backed a Nasdaq Stock Issuance (ELOC) Proposal ...
Business Operations and StrategyProduct-Related Announcements
GlucoTrack Strengthens IP for Implantable Glucose Monitoring Platform
Positive
Jan 29, 2026
On January 29, 2026, Glucotrack, Inc. announced that the U.S. Patent and Trademark Office had issued three patents in late 2025 covering key technologies underpinning its fully implantable continuous blood glucose monitoring platform, including pr...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.